Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Leuprorelin SR by Foresee Pharmaceuticals for Central Precocious Puberty: Likelihood of Approval
Leuprorelin SR is under clinical development by Foresee Pharmaceuticals and currently in Phase III for Central Precocious Puberty. According to...